Wealth Enhancement Advisory Services
MYGN icon

Wealth Enhancement Advisory Services’s Myriad Genetics MYGN Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Buy
72,114
+43,070
+148% +$195K ﹤0.01% 2859
2026
Q1 		$138K Sell
29,044
-7,944
-21% -$41.4K ﹤0.01% 3243
2025
Q4 		$241K Buy
36,988
+5,694
+18% +$41.3K ﹤0.01% 3112
2025
Q3 		$236K Buy
31,294
+5,029
+19% +$29.9K ﹤0.01% 2986
2025
Q2 		$147K Buy
+26,265
New +$155K ﹤0.01% 3072

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wealth Enhancement Advisory Services's MYGN Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Myriad Genetics (MYGN) stake by 148% in Q2 2026, buying an estimated $195K and bringing the position to 72,114 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #2859.

Wealth Enhancement Advisory Services first reported a position in MYGN in Q2 2025 and has held it in 5 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Wealth Enhancement Advisory Services held 72,114 shares of Myriad Genetics worth $420K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 43,070 Myriad Genetics shares in Q2 2026, an estimated $195K.
  • Myriad Genetics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2859 holding.
  • Wealth Enhancement Advisory Services first reported a position in Myriad Genetics in Q2 2025 and has held it in 5 quarters since.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.